Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals company information, Employees & Contact Information

At Arrowhead Pharmaceuticals we are breaking the mold of medicine. We are pushing the boundaries of therapeutic development and revolutionizing how we care for hard-to-treat illnesses. As a company we harness collaboration and innovation to rapidly advance drugs from discovery to the clinic. All applicants: Please be aware of employment scams using Arrowhead’s name and the names of Arrowhead’s employees. All job related Arrowhead communication should come from the domain @arrowheadpharma.com.

Company Details

Employees
625
Address
177 E Colorado Blvd, Suite 700,united States
Phone
(626) 304-3400
Email
in****@****res.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Pasadena, California
Looking for a particular Arrowhead Pharmaceuticals employee's phone or email?

Arrowhead Pharmaceuticals Questions

News

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia - Yahoo Finance

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia Yahoo Finance

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement - Business Wire

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement Business Wire

Arrowhead Lands Massive $395M China Deal with Sanofi for Revolutionary Triglyceride Drug - Stock Titan

Arrowhead Lands Massive $395M China Deal with Sanofi for Revolutionary Triglyceride Drug Stock Titan

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results - Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results Business Wire

Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street - Sixth Street

Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street Sixth Street

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences - Business Wire

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences Business Wire

GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen - GSK

GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen GSK

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity - Business Wire

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity Business Wire

Arrowhead Strengthens Balance Sheet with Unique $100M Milestone Payment Strategy from Sarepta - Stock Titan

Arrowhead Strengthens Balance Sheet with Unique $100M Milestone Payment Strategy from Sarepta Stock Titan

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Business Wire

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome Business Wire

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals - Business Wire

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals Business Wire

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics - Business Wire

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences - Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences Business Wire

Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome - Business Wire

Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome Business Wire

Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs - Business Wire

Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs Business Wire

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran - Business Wire

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran Business Wire

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity - Business Wire

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity Business Wire

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - Business Wire

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome Business Wire

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for - PharmiWeb.com

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for PharmiWeb.com

Arrowhead Pharmaceuticals Announces Retirement of COO Bruce Given - Pasadena Now

Arrowhead Pharmaceuticals Announces Retirement of COO Bruce Given Pasadena Now

ARO-AAT Receives Fast Track Status for Treatment of Rare Genetic Liver Disease - Medical Professionals Reference

ARO-AAT Receives Fast Track Status for Treatment of Rare Genetic Liver Disease Medical Professionals Reference

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - FinancialContent

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) FinancialContent

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - FinancialContent

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) FinancialContent

UW-Madison technology enlisted in battle against hepatitis B - University of Wisconsin–Madison

UW-Madison technology enlisted in battle against hepatitis B University of Wisconsin–Madison

Top Arrowhead Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant